(Q36066048)

12 August 2017

1 reference

title

Therapy for haemophilia: recent advances and goals for the future (English)

1 reference

12 August 2017

0 references

Guy Young

1

1 reference

12 August 2017

Louis Aledort

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

173-184

1 reference

Hemophilia. A new approach to an old disease.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

The hemophilias--from royal genes to gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Home management of haemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Hemophilia: treatment options in the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Haemophilia prophylaxis in young patients--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Why is primary prophylaxis underutilized in the United States?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Evolving perspectives in product safety for haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

TT virus contaminates first-generation recombinant factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

TT virus does not contaminate first-generation recombinant factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Gene therapy for hemophilia? Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Prospects for gene therapy of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

The future of recombinant coagulation factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Molecular basis for different ability of low-density and high-density lipoproteins to support activity of the intrinsic Xase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Coagulation factors with improved properties for hemophilia gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Transgenic pigs produce functional human factor VIII in milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Expression of factor VIII in recombinant and transgenic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Inhibitors: resolving diagnostic and therapeutic dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Dosing with recombinant factor viia based on current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Decreased mortality of ischaemic heart disease among carriers of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Mortality and causes of death in Dutch haemophiliacs, 1973-86.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

Gene therapy for hemophilia? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.173

10.1517/14728214.10.1.173

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference